Clinical laboratories must ensure that accurate, reliable, and timely test results are provided to clinicians
Join us for a free webinar presented by Jeffrey S. Jhang, MD, assistant professor of clinical pathology and cell biology, New York Presbyterian Hospital/Columbia University Medical Center.
Warfarin and heparin anticoagulation can effectively treat or prevent thrombosis, but they are high-risk therapies because of their narrow therapeutic windows; the need for complex dosing algorithms; the requirement of close laboratory monitoring. Excessive anticoagulation increases the risk of bleeding complications, which can range from asymptomatic to massive hemorrhage and death. Newer anticoagulants, such as direct thrombin inhibitors or factor Xa inhibitors do not require laboratory monitoring, but they still carry a significant risk of bleeding.
Clinical laboratories must ensure that accurate, reliable and timely test results are provided to clinicians. However, this is not sufficient to provide safe anticoagulation therapy. Laboratories must also participate in establishing therapeutic ranges, writing anticoagulation dosing and monitoring guidelines, and providing consultation for providing therapy for the rapid anticoagulation reversal in the setting of excess anticoagulation with bleeding or imminent surgery. The goal of this presentation is to review anticoagulation management with warfarin, heparin, direct thrombin inhibitors and factor Xa inhibitors. We will then discuss strategies to improve patient safety by establishing guidelines for ordering laboratory studies prior to initiating anticoagulation, validating therapeutic ranges, setting up critical values and policies, and developing guidelines for the reversal of anticoagulation with blood products and pharmaceuticals.
About the Sponsor: Instrumentation Laboratory
Instrumentation Laboratory ( www.ilus.com ), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include Hemostasis systems, Critical Care systems, and Information Management systems. IL’s Hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, ACL TOP 500 CTS and ACL TOP 300 CTS. IL also offers the ACL AcuStar®, ACL ELITE®, other Hemostasis analyzers and the HemosIL® line of reagents. IL’s GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers. IL is based in Bedford, Mass.